J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
This article was originally published in The Pink Sheet Daily
Executive Summary
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
You may also be interested in...
Clinical Trial Data Sharing: Central Public-Private Portal May Expand Access
J&J has gotten 25 requests for data through YODA project; BMJ study ranks GSK, J&J, Pfizer highest in making data publicly available and Gilead lowest.
BIO 2015 Dispatches: Data Transparency Initiatives Could Deter Industry Investment, Attorney Says
Covington partner Richard Kingham says early disclosure of clinical data could impede sponsor efforts to secure patents, driving away potential investors in the process. But EMA's Hans-Georg Eichler says investors should welcome the initiatives because they will bring greater efficiency to drug development.
Clinical Trial Transparency Gets A Boost With J&J Agreement, IOM Report
Johnson & Johnson's device and diagnostic clinical trial data is now available to independent researchers via Yale University’s Open Data Access (YODA) Project, announced the same day as an Institute of Medicine report mapping out strategies for clinical trial data-sharing.